⌘K
Loading ticker…
As of 2026-08-24, Aardvark Therapeutics, Inc. Common Stock (AARD) has a 3-month relative strength percentile of 94 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 48. The current market Stance is 47.8 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 13.5%, relative volume 0.65×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
Daily range, ATR, beta, and the math for a 1-ADR stop.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
YoY sales growth, last 8 quarters. Sales must back the earnings story.
Operating margin unavailable
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
AARD is held by 13 ETFs as of May 2026. Top owner: VTWO at 0.00% weight, $267K notional. Top 3 carry $387K.
Held by 20 ETFs · $5M across latest filings · largest weight 0.06% (SBIO).
Top 10 by value, from SEC N-PORT-P filings dated May 2026.
| ETF | Weight | Value | Δ |
|---|---|---|---|
| VTWO | 0.00% | $267K | — |
| SBIO | 0.06% | $92K | −0.12 pp |
| VTWG | 0.00% | $28K | — |
| OMFS | 0.01% | $18K | new |
| VTWV | 0.00% | $18K | — |
| VTHRVanguard Russell 3000 ETF | 0.00% | $6K | — |
| IBBQ | 0.01% | $5K | −0.01 pp |
| BIB | 0.00% | $3K | — |
| ITWO | 0.00% | $2K | — |
| URTY | 0.00% | $2K | — |
Showing 10 of 13 ETF owners.
As filed in N-PORT — quarterly holdings with up to ~60-day publication lag. Not live positioning.
Strong relative strength with attention running hot versus its own recent norm. The trend is intact but well-noticed; elevated retail attention has historically been associated with softer forward returns. Context, not a call.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
News
Related searches
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | AARD Jan avg: -1.03% median: -1.03% win: 0% σ: 0.00% n: 1 2025-02-14 → 2026-07-31 | AARD Feb avg: -7.45% median: -7.45% win: 0% σ: 5.09% n: 2 2025-02-14 → 2026-07-31 | AARD Mar avg: -55.41% median: -55.41% win: 0% σ: 20.37% n: 2 2025-02-14 → 2026-07-31 | AARD Apr avg: 45.98% median: 45.98% win: 100% σ: 2.76% n: 2 2025-02-14 → 2026-07-31 | AARD May avg: -15.17% median: -15.17% win: 0% σ: 12.93% n: 2 2025-02-14 → 2026-07-31 | AARD Jun avg: 34.82% median: 34.82% win: 100% σ: 7.53% n: 2 2025-02-14 → 2026-07-31 | AARD Jul avg: 1.71% median: 1.71% win: 50% σ: 18.21% n: 2 2025-02-14 → 2026-07-31 | AARD Aug avg: -30.89% median: -30.89% win: 0% σ: 0.00% n: 1 2025-02-14 → 2026-07-31 (current) | AARD Sep avg: 60.12% median: 60.12% win: 100% σ: 0.00% n: 1 2025-02-14 → 2026-07-31 | AARD Oct avg: -19.56% median: -19.56% win: 0% σ: 0.00% n: 1 2025-02-14 → 2026-07-31 | AARD Nov avg: -6.64% median: -6.64% win: 0% σ: 0.00% n: 1 2025-02-14 → 2026-07-31 | AARD Dec avg: 31.51% median: 31.51% win: 100% σ: 0.00% n: 1 2025-02-14 → 2026-07-31 |